Abstract
Nicotine replacement is currently the only approved pharmacologic treatment for smoking cessation, and for several years, the only formulation available has been nicotine chewing gum. While placebo controlled trials have shown that nicotine gum increases success rates when used as an adjunct to a behavioral treatment program, overall abstinence rates 6–12 months after initial cessation remain low. In a recent review of several clinical studies by Fagerstrom1, abstinence rates averaged 26% with active gum treatment versus 16% with placebo gum. In an attempt to increase the magnitude of treatment effects, other routes of nicotine administration have been explored, including transdermal and intranasal routes. The hope is that an appropriate rate and dose of nicotine replacement can relieve smoking withdrawal symptoms and can greatly reduce the tendency of a smoker to relapse. However, one must be cautious to avoid a simplistic characterization of cigarette smoking. For example, while most people are aware that smoking is more than just a habit, it is also more complex than simply an addiction to nicotine, at least as that concept is often understood. In fact, both of these views are incomplete, and the development of effective treatments for smoking cessation may hinge on an understanding of the subtle interactions between conditioned cues and pharmacologic factors involved in the maintenance of smoking behavior. Before discussing the therapeutic application of both transdermal nicotine administration and nasal nicotine administration as adjuncts to smoking-cessation treatment, it will be helpful to review what we know about smoking and its relationship to nicotine dependence.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Fagerstrom KO. Efficacy of nicotine chewing gum: A review. In: Pomerleau OF, Pomerleau CS, Nicotine replacement: A critical evaluation. New York: Liss, 1988: 109–128.
Armitage AK, Hall GH, Morrison CF. Pharmacological basis for the tobacco smoking habit. Nature 1968; 217: 331–334.
Russell MAH. Nicotine intake and its control over smoking. In: Wonnacott S, Russell MAH, Stolerman IP, eds. Nicotine psychopharmacology: Molecular, cellular, and behavioral aspects. New York: Oxford University Press, 1990: 347–418.
Kellar KJ, Wonnacott S. Nicotinic cholinergic receptors in Alzheimer’s disease. In: Wonnacott S, Russell MAH, Stolerman IP, eds. Nicotine psycho-pharmacology: Molecular, cellular, and behavioral aspects. New York Oxford University Press, 1990: 341–373.
Reavill C. Action of nicotine on dopamine pathways and implications for Parkinson’s disease. In: Wonnacott S, Russell MAH, Stolerman IP, eds. Nicotine psychopharmacology: Molecular, cellular, and behavioral aspects. New York: Oxford University Press, 1990: 307–340.
Benowitz, NL, Porchet H, Jacob P. Pharmacokinetics, metabolism, and pharmacodynamics of nicotine. In: Wonnacott S, Russell MAH, Stolerman IP, eds. Nicotine psychopharmacology: Molecular, cellular, and behavioral aspects. New York: Oxford University Press, 1990: 112–157.
Fuxe K, Andersson K, Harfstrand A, Eneroth P, de la Mora MP, Agnati LF. Effects of nicotine on synaptic transmission in the brain. In: Wonnacott S, Russell MAH, Stolerman IP, eds. Nicotine psychopharmacology: Molecular, cellular, and behavioral aspects. New York: Oxford University Press, 1990: 194–225.
Pomerleau OF, Rosecrans J. Neuroregulatory effects of nicotine. Psychoneuroendocrinology 1989; 14: 1–17.
Wonnacott S. Characterization of nicotine receptor sites in the brain. In: Wonnacott S, Russell MAH, Stolerman IP, eds. Nicotine psychopharmacology: Molecular, cellular, and behavioral aspects. New York: Oxford University Press, 1990: 226–277.
Warburton DM. Psychopharmacological aspects of nicotine. In: Wonnacott S, Russell MAH, Stolerman IP, eds. Nicotine psychopharmacology: Molecular, cellular, and behavioral aspects. New York: Oxford University Press, 1990: 77–111.
Levin E, Lee C, Rose JE, Reyes A, Ellison G, Jarvik M, Gritz E. Chronic nicotine and withdrawal effects on radial-arm maze performance. Behav and Neural Biol 1990; 53: 269–276.
Grunberg NE. The effects of nicotine and cigarette smoking on food consumption and taste preferences. Addict Behav 1982; 7: 317–331.
Cherek DR. Effects of smoking different doses of nicotine on human aggressive behavior. Psychopharmacology 1981; 75: 339–345.
Jaffe JH. Tobacco smoking and nicotine dependence. In: Wonnacott S, Russell MAH, Stolerman IP, eds. Nicotine psychopharmacology: Molecular, cellular, and behavioral aspects. New York: Oxford University Press, 1990: 1–37.
Herman CP, Kozlowski LT. Indulgence, excess, and restraint: Perspectives on consummatory behavior in everyday life. J of Drug Issues 1979; 9: 185–196.
Kumar R, Cooke EC, Lader MH, Russell MAH. Is nicotine important in tobacco smoking? Clin Pharmacol Ther 1967; 21: 520–529.
Lucchesi BR, Schuster CR, Emley GS. The role of nicotine as a determinant of cigarette smoking frequency in man with observations of certain cardiovascular effects associated with the tobacco alkaloid. Clin Pharmacol Ther 1967; 89: 789–796.
Henningfield JE Woodson PP. Behavioral and physiologic aspects of nicotine dependence: the role of nicotine dose. In: Nordberg A, Fuxe K, Holmstedt B, Sundwall A. Progress in brain research. Vol. 79. Elsevier Science Publishers B. V., 1989: 303–312.
Fertig JB, Pomerleau OF, Sanders B. Nicotine-produced antinociception in minimally deprived smokers and ex-smokers. Addict Behav 1986; 11: 239–248.
Rose JE, Tashkin DP, Ertle A, Zinser MC, Lafer R. Sensory blockade of smoking satisfaction. Pharmacol Biochem Behav 1985; 23: 289–293.
Rose JE. The role of upper airway stimulation in smoking: In: Pomerleau O. F, Pomerleau C. S, eds. Nicotine replacement in the treatment of smoking: A critical evaluation. New York: Liss, 1988: 95–106.
Jasinski DR, Henningfield JE. Conceptual basis of replacement therapies for chemical dependence. In: Pomerleau OF, Pomerleau CS, eds. Nicotine replacement in the treatment of smoking: A critical evaluation. New York: Liss, 1988: 13–34.
Hughes JR. Problems of nicotine gum. In: Okene JK, ed. The pharmacologic treatment of tobacco dependence: Proceedings of the World Congress. November 4–5, 1985. Cambridge, MA: Institute for the Study of Smoking Behavior and Policy, 1986: 141–147.
Rose JE. Transdermal nicotine as a strategy for nicotine replacement. In: The pharmacologic treatment of tobacco dependence: Proceedings of the World Congress. November 4–5, 1985. Okene JK ed. Cambridge, MA: Institute for the Study of Smoking Behavior and Policy, 1986: 158–166.
Rose JE, Jarvik ME, Rose KD. Transdermal administration of nicotine. Drug and Alcohol Dependence 1984; 13: 209–213.
Rose JE, Herskovic JE, Trilling Y, Jarvik ME. Transdermal nicotine reduces cigarette craving and nicotine preference. Clin Pharmacol Ther 1985; 38: 450–456.
Mulligan SC, Masterson JG, Devane JG, Kelly JG. Clinical and pharmacokinetic properties of a transdermal nicotine patch. Clin Pharmacol Ther 1990; 47: 331–337.
Dubois JP, Siouf A, Muller P, Mauli D, Imhof PR. Pharmacokinetics and bioavailability of nicotine in healthy volunteers following single and repeated administration of different doses of transdermal nicotine systems. Meth and Findings in Exper and Clin Pharmacol 1989; 11: 187–195.
Abelin T, Buehler A, Muller P, Imhof PR. Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet Vol. 1, 1989: 7–10.
Abelin T, Ehrsam R, Buhler-Reichert A, Imhof PR, Muller P, Thommen A, Vasanen K. Effectiveness of a transdermal nicotine system in smoking cessation studies. Meth and Findings in Exper and Clin Pharmacol 1989; 11: 205–214.
Krumpe P, Malani N, Adler J, Ramoorthy S, Asadi S, Corwin N, Dolan P, Geismar L. Efficacy of transdermal nicotine as an adjunct for smoking cessation in heavily nicotine addicted smokers. Amer Rev of Respir Disease 1989; 139: A337.
Rose JE, Levin ED, Behm FM, Adivi C, Schur C. Transdermal nicotine facilitates smoking cessation. Clin Pharmacol Ther 1990; 47: 323–330.
Buchkremer G, Minneker E. Efficiency of multimodal smoking cessation therapy combining transdermal nicotine substitution with behavioral therapy. Meth and Findings in Exper and Clin Pharmacol 1989; 11: 215–218.
Fagerstrom KO, Lunell E, Molander L, Forshell GP, Sawe U, Continuous and intermittent transdermal delivery of nicotine and blockade of withdrawal symptoms. Presented at the Seventh World Conference on Tobacco and Health. Perth, Australia, April, 1990.
Hughes JR, Hatsukami DK, Pickens RW, Krahn D, Malin S, Luknic A. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 1984; 83: 82–87.
Shiffman SM, Jarvik ME. Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology 1976; 50: 35–39.
Eichelberg E, Stolze P, Block M, Buchkremer G. Contact allergies induced by TTS-treatment. Meth and Findings in Exper and Clin Pharmacol 1989; 11: 223–225.
Russell MAH, Jarvis MJ, Feyerbend C, Ferno O. Nasal nicotine solution: A potential aid to giving up smoking? Brit Med J 1983; 286: 683–684.
Jarvis MJ, Hajek P, Russell MAH, West RJ Feyerabend C. Nasal nicotine solution as an aid to cigarette withdrawal: A pilot clinical trial. Brit J of Addict 1987; 83: 323–330.
Hughes JR, Gust SW, Keenan RM, Fenwick JW. Effect of dose on nicotine’s reinforcing, withdrawal-suppression and self-reported effects. J of Pharmacol Exper Ther 1990; 252: 1175–1183.
Shiffman S. Relapse following smoking cessation: A situational analysis. J of Consult Clin Psychol 1982; 50; 71–86.
Behm FM, Levin ED, Lee YK, Rose JE. Low-nicotine smoke aerosol reduces desire for cigarettes. J Subst Abuse 1990; 2: 237–247.
Levin ED, Rose JE, Behm FB. Development of a citric acid aerosol as a smoking cessation aid. Drug and Alcohol Dependence 1990; 25: 273–279.
Rose JE, Behm FM. Refined cigarette smoke as a means to reduce nicotine intake. Pharmacol Biochem Behav 1987; 28: 305–310.
Rose JE, Hickman C. Citric acid aerosol as a potential smoking cessation aid. Chest 1988; 92: 1005–1008.
Rose, JE. Discussion. In: The biology of nicotine dependence. Chichester, England: Wiley, 1990: 82.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag New York Inc.
About this chapter
Cite this chapter
Rose, J.E. (1991). Transdermal Nicotine and Nasal Nicotine Administration as Smoking-Cessation Treatments. In: Cocores, J.A. (eds) The Clinical Management of Nicotine Dependence. Springer, New York, NY. https://doi.org/10.1007/978-1-4613-9112-8_16
Download citation
DOI: https://doi.org/10.1007/978-1-4613-9112-8_16
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4613-9114-2
Online ISBN: 978-1-4613-9112-8
eBook Packages: Springer Book Archive